General Pharmacology Practice Questions

Q: Which of the following is a prodrug of cetirizine?

Hydroxyzine. **Explanation:** **1. Why Hydroxyzine is the Correct Answer:** Hydroxyzine is a first-generation H1-receptor antagonist. It undergoes extensive hepatic metabolism via the enzyme **alcohol dehydrogenase** to form its active carboxylic acid metabolite, **Cetirizine**. Since Cetirizine is the active form responsible for a significant portion of the drug's antihistaminic effect, Hydroxyzine is considered the prodrug of Cetirizine. This conversion explains why Cetirizine (a second-generation agent) is less sedating; it is a polar metabolite that does not cross the blood-brain barrier as readily as its parent compound, Hydroxyzine. **2. Analysis of Incorrect Options:** * **A. Fexofenadine:** This is the active metabolite of **Terfenadine**. It is not a prodrug but a second-generation antihistamine itself. * **B. Terfenadine:** This is a prodrug of **Fexofenadine**. It was withdrawn from the market because the parent drug (Terfenadine) caused QT interval prolongation and *Torsades de Pointes* when its metabolism was inhibited (e.g., by erythromycin or ketoconazole). * **D. Azelastine:** This is a second-generation antihistamine primarily used as a nasal spray or ophthalmic drop for allergic rhinitis and conjunctivitis. It is not a prodrug of cetirizine. **3. NEET-PG High-Yield Pearls:** * **Metabolite Pairs:** Always remember: Hydroxyzine → Cetirizine; Terfenadine → Fexofenadine; Loratadine → Desloratadine. * **Safety Profile:** Cetirizine is unique among second-generation antihistamines as it can cause mild sedation in some patients, unlike Fexofenadine, which is considered non-sedating even at high doses. * **Clinical Use:** Hydroxyzine is frequently used for its sedative and anti-pruritic properties in dermatological conditions and anxiety.

Q: All of the following drugs are used as immunosuppressants except?

Cephalosporin. ### Explanation The correct answer is **Cephalosporin** because it is an **antibiotic**, not an immunosuppressant. #### 1. Why Cephalosporin is the Correct Choice Cephalosporins are **Beta-lactam antibiotics** derived from the fungus *Acremonium*. They work by inhibiting bacterial cell wall synthesis (binding to Penicillin-Binding Proteins). They have no inherent activity in suppressing the human immune system and are used to treat bacterial infections. #### 2. Analysis of Other Options (Immunosuppressants) * **Glucocorticoids (Option A):** These are the most commonly used immunosuppressants. They act by inhibiting the expression of multiple inflammatory genes (NF-κB pathway), decreasing cytokine production (IL-1, IL-2, IL-6), and causing T-cell apoptosis. * **Cyclosporin (Option B):** A **Calcineurin inhibitor**. It binds to cyclophilin to inhibit calcineurin, preventing the dephosphorylation of NFAT (Nuclear Factor of Activated T-cells). This specifically blocks the synthesis of **Interleukin-2 (IL-2)**, a key driver of T-cell proliferation. * **Azathioprine (Option D):** A **Cytotoxic/Antimetabolite** drug. It is a prodrug of 6-mercaptopurine (6-MP) that inhibits purine synthesis, thereby preventing the proliferation of rapidly dividing B and T lymphocytes. #### 3. NEET-PG High-Yield Pearls * **Confusion Point:** Students often confuse **Cyclosporin** (Immunosuppressant) with **Cephalosporin** (Antibiotic) or **Cycloserine** (Anti-TB drug) due to similar nomenclature. * **Cyclosporin Side Effects:** Remember the "6 H's"—Hypertrichosis (hirsutism), Hyperplasia (gingival), Hypertension, Hyperlipidemia, Hyperkalemia, and **Hepatotoxicity/Nephrotoxicity**. * **Azathioprine Interaction:** It is metabolized by **Xanthine Oxidase**. Therefore, its dose must be reduced by 50-75% if the patient is also taking **Allopurinol** to avoid life-threatening bone marrow suppression.

Q: Loading dose of a drug primarily depends on which pharmacokinetic parameter?

Volume of distribution. **Explanation:** The **Loading Dose (LD)** is a large initial dose given to achieve the **target plasma concentration ($C_p$)** rapidly. It is primarily determined by the **Volume of Distribution ($V_d$)**. The mathematical relationship is: $$\text{Loading Dose} = V_d \times \text{Target } C_p$$ Since the goal of a loading dose is to "fill up" the body's various compartments (tissues and plasma) to reach a steady state immediately, the drug's distribution characteristics ($V_d$) are the most critical factor. **Analysis of Options:** * **B. Clearance (CL):** This determines the **Maintenance Dose (MD)**, which is the dose required to replace the drug being eliminated to maintain a steady state. * **C. Rate of Administration:** While important for safety (to avoid toxicity from rapid IV push), it does not determine the calculated dose required to reach a target concentration. * **D. Half-life ($t_{1/2}$):** This determines the **time taken** to reach steady state (usually 4–5 half-lives) without a loading dose, but it does not dictate the size of the loading dose itself. **High-Yield Clinical Pearls for NEET-PG:** 1. **Loading Dose** = Rapidly reaches therapeutic levels; **Maintenance Dose** = Maintains steady state. 2. **Renal/Hepatic Failure:** In these conditions, clearance is reduced, so the **Maintenance Dose must be decreased**. However, the **Loading Dose remains the same** (unless the $V_d$ is significantly altered). 3. **Digoxin and Amiodarone:** These are classic examples of drugs requiring loading doses due to their large $V_d$ and long half-lives. 4. **Bioavailability (F):** If a drug is given orally, the formula becomes: $LD = (V_d \times \text{Target } C_p) / F$.

Q: Which of the following statements regarding plasma protein binding is NOT true?

Nephrotic syndrome does not affect plasma protein binding.. ### Explanation **1. Why Option C is the Correct Answer (The "NOT True" Statement):** Plasma protein binding is significantly altered in **Nephrotic Syndrome**. This condition is characterized by massive proteinuria, leading to **hypoalbuminemia**. Since many drugs (especially acidic ones) rely on albumin for transport, a decrease in albumin levels results in a higher **free fraction** of the drug. This can lead to increased pharmacological effects or potential toxicity even at standard doses. Therefore, saying it "does not affect" binding is medically incorrect. **2. Analysis of Incorrect Options:** * **Option A:** This is a fundamental principle. Only the **free (unbound) fraction** can cross biological membranes, interact with receptors, and undergo metabolism/excretion. The bound fraction acts as a reservoir. * **Option B:** Generally, **acidic drugs** (e.g., NSAIDs, Warfarin, Phenytoin) bind to **Albumin**, while **basic drugs** (e.g., Lidocaine, Propranolol) bind to **Alpha-1-acid glycoprotein (AAG)**. * **Option D:** Prazosin is a basic drug. Basic drugs predominantly bind to **Alpha-1-acid glycoprotein**, making this statement true. **3. High-Yield Clinical Pearls for NEET-PG:** * **Albumin vs. AAG:** Albumin levels decrease in liver disease and nephrotic syndrome. AAG is an "acute-phase reactant"; its levels **increase** during inflammation, surgery, or myocardial infarction, potentially decreasing the free fraction of basic drugs. * **Displacement Interactions:** Highly protein-bound drugs (e.g., Warfarin) can be displaced by other drugs (e.g., Sulfonamides), leading to a sudden spike in the free fraction and toxicity. * **Volume of Distribution (Vd):** Drugs with high plasma protein binding typically have a **low Vd**, as they are sequestered within the vascular compartment.

Q: What is true about intracellular receptors?

They are mainly on the nuclear surface.. **Explanation:** Intracellular receptors (also known as nuclear receptors) are a class of receptors located inside the cell, rather than on the plasma membrane. These receptors function as ligand-activated transcription factors. **1. Why Option A is correct:** Intracellular receptors are located either in the **cytoplasm** (e.g., glucocorticoids, mineralocorticoids) or directly in the **nucleus** (e.g., estrogen, thyroid hormones). Even cytoplasmic receptors, once bound to their ligand, must translocate to the nucleus to bind to specific DNA sequences (Hormone Response Elements). Therefore, their primary site of action and predominant location for gene regulation is the **nuclear surface/matrix.** **2. Why the other options are incorrect:** * **Option B:** Growth hormone (GH) is a peptide hormone. It acts via **cell surface receptors** (specifically, JAK-STAT kinase-linked receptors), not intracellular receptors. * **Option C:** Estrogen is a steroid hormone. Being lipophilic, it easily crosses the cell membrane and acts specifically on **intracellular (nuclear) receptors** to regulate gene expression. **NEET-PG High-Yield Pearls:** * **Mnemonic for Intracellular Receptors:** **"VET CAPS"** – **V**itamin A & D, **E**strogen, **T**hyroid hormone (T3/T4), **C**ortisol (Glucocorticoids), **A**ldosterone (Mineralocorticoids), **P**rogesterone, and **S**ex hormones (Testosterone). * **Mechanism:** These receptors have a specific **Zinc-finger motif** in their DNA-binding domain. * **Lag Period:** Because they act by altering protein synthesis (transcription/translation), their effects have a slow onset (hours to days) and a long duration of action.

Q: Which of the following is the 'ordeal poison' used by tribes of Africa?

Physostigmine. **Explanation:** **Physostigmine (Option A)** is the correct answer. It is a naturally occurring tertiary amine carbamate obtained from the **Calabar bean** (*Physostigma venenosum*). Historically, these beans were used by West African tribes in "trials by ordeal" to determine guilt or innocence. A person accused of a crime would ingest the beans; if they vomited (survived), they were declared innocent, but if they succumbed to the toxic effects (miosis, skeletal muscle paralysis, and respiratory failure), they were deemed guilty. **Why the other options are incorrect:** * **Digoxin (Option B):** A cardiac glycoside derived from *Digitalis lanata*. It is used for heart failure and atrial fibrillation but has no historical association with ordeal trials. * **Cocaine (Option C):** An alkaloid from *Erythroxylum coca* used as a local anesthetic and drug of abuse; it acts as a sympathomimetic. * **Atropine (Option D):** An anticholinergic derived from *Atropa belladonna*. Interestingly, it is the **pharmacological antidote** for physostigmine poisoning, as it competes at muscarinic receptors. **High-Yield NEET-PG Pearls:** * **Lipid Solubility:** Unlike Neostigmine, Physostigmine is a **tertiary amine**, meaning it is lipid-soluble and **crosses the blood-brain barrier (BBB)**. * **Clinical Use:** It is the drug of choice for **Atropine poisoning** (Anticholinergic syndrome). * **Mechanism:** It is a reversible anticholinesterase that increases acetylcholine levels at both muscarinic and nicotinic sites. * **Mnemonic:** "Physostigmine **P**hixes (fixes) the **P**eriphery and the **P**syche (CNS)."

Q: Which of the following is not an enzyme inhibitor?

Griseofulvin. ### Explanation The correct answer is **Griseofulvin** because it is a potent **microsomal enzyme inducer**, not an inhibitor. #### 1. Why Griseofulvin is the Correct Answer In pharmacology, drugs that affect the Cytochrome P450 (CYP450) system are classified as either inducers or inhibitors. **Griseofulvin** increases the synthesis of microsomal enzymes. This leads to the accelerated metabolism of co-administered drugs (like warfarin or oral contraceptives), potentially reducing their therapeutic efficacy. #### 2. Analysis of Incorrect Options (Enzyme Inhibitors) The other options are classic examples of enzyme inhibitors, which decrease CYP450 activity, leading to increased plasma levels and potential toxicity of other drugs: * **Isoniazid (INH):** A primary anti-tubercular drug known to inhibit enzymes, often leading to interactions with phenytoin. * **Ketoconazole:** An antifungal that strongly inhibits CYP3A4; it is a frequent "distractor" in exam questions regarding drug interactions. * **Acute Alcohol Intoxication:** Acute ingestion of alcohol competes for metabolic pathways and inhibits the metabolism of other drugs. (Note: *Chronic* alcohol consumption is an enzyme inducer). #### 3. High-Yield Clinical Pearls for NEET-PG To quickly solve "Inducer vs. Inhibitor" questions, remember these mnemonics: * **Enzyme Inducers (GPRS Cell Phone):** * **G**riseofulvin * **P**henytoin / **P**henobarbitone * **R**ifampicin (Strongest inducer) * **S**moking / **S**t. John’s Wort * **C**arbamazepine * **Enzyme Inhibitors (VITAMIN K):** * **V**alproate * **I**soniazid * **T**amoxifen * **A**miodarone * **M**acrolides (except Azithromycin) * **I**ndinavir * **N**efazodone * **K**etoconazole (and other Azoles) * *Also: Cimetidine, Grapefruit juice, and Acute Alcohol.*

Q: An investigator is studying a potential new antiarrhythmic. Eighty healthy test subjects are receiving various doses of the drug. Adverse effects and the drug’s pharmacokinetics are assessed. Which of the following steps in the drug development process does this represent?

Phase I. ### Explanation **Correct Answer: B. Phase I** The scenario describes **Phase I clinical trials**, which are the first stage of testing a new drug in humans [1]. The primary goal of Phase I is to assess **safety, tolerability, and pharmacokinetics** (ADME: Absorption, Distribution, Metabolism, and Excretion) [3]. **Why Phase I is correct:** * **Subjects:** It typically involves a small group (**20–100**) of **healthy volunteers** [3] (except for highly toxic drugs like anti-cancer agents, where patients are used). * **Objective:** To determine the maximum tolerated dose and identify common side effects [3]. The mention of "80 healthy test subjects" and "pharmacokinetics" are classic indicators of Phase I. **Why other options are incorrect:** * **Phase II:** Focuses on **efficacy** ("proof of concept") [1] and optimal dosing in a small group of **patients** (100–300) who actually have the disease. * **Phase III:** Involves large-scale, multicenter, randomized controlled trials (RCTs) in **thousands of patients** to confirm efficacy and monitor for rarer adverse effects compared to existing treatments. * **New Drug Application (NDA):** This is the formal proposal submitted to regulatory authorities (like the FDA or DCGI) *after* Phase III is successfully completed [1] to gain marketing approval. --- ### High-Yield Clinical Pearls for NEET-PG * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in <15 humans to study pharmacokinetics; it precedes Phase I. * **Phase IV (Post-marketing Surveillance):** Occurs after the drug is on the market to detect rare or long-term adverse effects (e.g., Phocomelia with Thalidomide) [2]. * **Trick for Subjects:** * Phase I = **H**ealthy volunteers (**H**ow safe?) * Phase II = **P**atients (**P**roof of concept) * Phase III = **L**arge scale (**L**egality/Approval) * **Success Rate:** Phase I has the highest success rate (~70%), while Phase II has the highest failure rate due to lack of efficacy [1].

Q: What is the advantage of a fixed-dose combination of drugs?

All of the above. Fixed-Dose Combinations (FDCs) involve two or more active pharmacological ingredients in a single pharmaceutical formulation. They are widely used in the management of chronic conditions like Hypertension, Diabetes, HIV, and Tuberculosis. **Why "All of the Above" is Correct:** 1. **Increases Efficacy (Option A):** FDCs often utilize **synergistic or additive effects** [4]. For example, combining a Sulfonylurea with Metformin targets two different pathological pathways of Diabetes, achieving better glycemic control than either drug alone at higher doses. 2. **Decreases Adverse Effects (Option B):** By combining drugs, one can often use lower doses of each component to achieve the same therapeutic effect, thereby reducing dose-dependent side effects [2]. Additionally, one drug may counteract the side effects of another (e.g., adding an ACE inhibitor to a Dihydropyridine Calcium Channel Blocker reduces the risk of peripheral edema). 3. **Improves Patient Compliance (Option C):** This is the most significant clinical advantage [1]. Reducing the **"pill burden"** simplifies the treatment regimen, making it easier for patients to adhere to their medication schedule, which is crucial for long-term outcomes [3]. **High-Yield NEET-PG Pearls:** * **Rational vs. Irrational FDCs:** A rational FDC must have ingredients that act by different mechanisms, have similar pharmacokinetics (half-lives), and should not lead to increased toxicity. * **Disadvantage:** The primary drawback of FDCs is the **lack of flexibility** in adjusting the dose of an individual component (titration difficulty). * **Classic Example:** Levodopa + Carbidopa. Carbidopa (a peripheral decarboxylase inhibitor) increases the efficacy of Levodopa in the CNS while decreasing peripheral side effects like nausea and vomiting.

Question 1

Which of the following is a prodrug of cetirizine?

Accepted Answer

Hydroxyzine

Answer

Foxefenadone

Answer

Terfenadine

Answer

Azelastine

Question 2

All of the following drugs are used as immunosuppressants except?

Accepted Answer

Cephalosporin

Answer

Glucocorticoids

Answer

Cyclosporin

Answer

Azathioprine

Question 3

Loading dose of a drug primarily depends on which pharmacokinetic parameter?

Accepted Answer

Volume of distribution

Answer

Clearance

Answer

Rate of administration

Answer

Half-life

Question 4

Which of the following statements regarding plasma protein binding is NOT true?

Accepted Answer

Nephrotic syndrome does not affect plasma protein binding.

Answer

The free fraction of a drug is considered pharmacologically active.

Answer

Acidic drugs typically bind to plasma albumin.

Answer

Prazosin is bound to alpha-1-acid glycoprotein.

Question 5

What is true about intracellular receptors?

Accepted Answer

They are mainly on the nuclear surface.

Answer

Growth hormone acts on them.

Answer

Estrogen does not act on them.

Answer

All of the above.

Question 6

Which of the following is the 'ordeal poison' used by tribes of Africa?

Accepted Answer

Physostigmine

Answer

Digoxin

Answer

Cocaine

Answer

Atropine

Question 7

Which schedule of drug is to be sold only on prescription?

Accepted Answer

H

Answer

P

Answer

G

Answer

X

Question 8

Which of the following is not an enzyme inhibitor?

Accepted Answer

Griseofulvin

Answer

Isoniazid

Answer

Ketoconazole

Answer

Acute alcohol intoxication

Question 9

An investigator is studying a potential new antiarrhythmic. Eighty healthy test subjects are receiving various doses of the drug. Adverse effects and the drug’s pharmacokinetics are assessed. Which of the following steps in the drug development process does this represent?

Accepted Answer

Phase I

Answer

New drug application (NDA)

Answer

Phase II

Answer

Phase III

Question 10

What is the advantage of a fixed-dose combination of drugs?

Accepted Answer

All of the above

Answer

Increases efficacy of drug

Answer

Decreases adverse effects

Answer

Patient compliance improved

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?